Drug Price Trends for CHILDRENS COLD AND COUGH LIQ

Average Pharmacy Cost for CHILDRENS COLD AND COUGH LIQ
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHILDRENS COLD AND COUGH LIQ | 00904-7531-20 | 0.01866 | ML | 2026-07-22 |
| CHILDRENS COLD AND COUGH LIQ | 70000-0715-01 | 0.01866 | ML | 2026-07-22 |
| CHILDRENS COLD AND COUGH LIQ | 00904-7531-20 | 0.01867 | ML | 2026-06-17 |
| CHILDRENS COLD AND COUGH LIQ | 70000-0715-01 | 0.01867 | ML | 2026-06-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Children’s Cold and Cough Liquid Market Analysis and Price Projections (US)
No market analysis or price projections can be produced for “CHILDRENS COLD AND COUGH LIQ” as stated because the request does not identify the drug’s active ingredients, dosage form strength, manufacturer/NDC, package size, branded vs OTC status, or whether it is an FDA-approved product with an Orange Book record. Without those identifiers, pricing and market sizing cannot be mapped to a specific product SKU and no defensible forecast can be generated.
What products are covered by “Children’s Cold and Cough Liquid” in the US OTC market?
Featured snippet answer: The phrase typically describes OTC pediatric combination cold/cough liquids, but the US market contains multiple product families with different active ingredients and strengths (e.g., antihistamines, decongestants, antitussives, expectorants, analgesics). Those differences drive price, payer dynamics (usually none for OTC), and competitive sets.
How ingredient combinations change the market and pricing
Pediatric cold/cough liquids commonly differ along these axes:
- Antihistamine component (sedating vs non-sedating; impacts consumer preference and formulation)
- Decongestant component (phenylephrine vs others; regulatory and label history affects demand)
- Antitussive component (dextromethorphan presence/absence)
- Expectorant component (guaifenesin presence/absence)
- Analgesic/antipyretic component (acetaminophen inclusion changes substitution patterns)
Why this matters for projections
OTC pricing is SKU-specific and sensitive to:
- ingredient set and FDA compliance outcomes
- distribution footprint (mass, club, grocery, online)
- pack size and concentration
- promotional intensity and retailer pricing algorithms
What drives price for pediatric OTC cold/cough liquids: ingredients, pack size, or retailer channel?
Featured snippet answer: For OTC children’s cold/cough liquids, the dominant price determinants are active-ingredient class, package size, and channel mix, with retailer promotions often dominating near-term realized prices.
Key pricing drivers
- Pack size and bottle count: larger bottles often show lower unit price, but may face lower velocity depending on household stocking behavior.
- Channel: grocery and mass show different promo calendars; club and drugstore differ in private-label penetration.
- Trade-down behavior: families shift to store brands when branded price-per-oz rises.
- Seasonality: Q4 to Q1 typically drives demand surges, changing promo depth and shelf pricing.
Expected behavior across seasons (projection logic)
- Retailers tend to price aggressively ahead of peak respiratory season.
- Volatility rises in years with strong winter demand or supply constraints.
- Ingredient compliance changes can shift demand across SKUs even if headline prices look stable.
How big is the US market for pediatric cold and cough liquid products?
Featured snippet answer: The US market is fragmented across many brands, store brands, and private labels; market size depends on whether “cold and cough liquids” are defined by indication label (cold, cough, congestion) and by age range claims (children/pediatric).
Market sizing requirements that are product-specific
To compute a defensible total addressable market (TAM) and forecast, the product must be mapped to:
- a single NDC/label strength (or a narrow ingredient set)
- a consistent pack size definition (mL/oz, count)
- an OTC category taxonomy used in market databases
Because “CHILDRENS COLD AND COUGH LIQ” is not uniquely identifying, no credible US TAM can be calculated from the request as written.
When does the product change price most: pre-season promotions or peak season?
Featured snippet answer: OTC children’s cold and cough liquids generally see the largest realized price changes in the pre-peak period when retailers reset promotional plans, then stabilize or soften discounting during peak demand.
Forecast implications
A usable projection requires:
- baseline historical weekly or monthly price series for the exact SKU
- promotional calendar mapping at retailer or channel level
- seasonality model parameters tied to that exact product’s category and velocity
These inputs cannot be anchored to the request without an identified product/SKU.
What competitive set determines your price floor and ceiling for pediatric cold/cough liquid?
Featured snippet answer: The competitive set for pricing is defined by therapeutic function overlap (cough and cold symptom coverage) and pediatric label positioning, plus store-brand alternatives at the same unit economics.
Competitive set components
- branded OTC products with the same ingredient classes
- private label liquids at similar pack size
- alternative dosage forms (chewables, syrups, dissolvable strips) that pull demand even when they are not the same exact symptom profile
How strong is the patent or exclusivity position for “Children’s Cold and Cough Liquid”?
Featured snippet answer: OTC pediatric cold/cough liquids are typically not protected by meaningful patent estates that map to prescription-drug-style Orange Book exclusivity. Price competition is usually driven by formulation equivalence, ingredient availability, and retailer private label.
Why patent analysis is not actionable from the request
Patent status requires:
- drug identity and active ingredient claims
- specific brand/formulation mapping to patent assignees and Orange Book entries
- jurisdiction-specific filings
The request provides no ingredient composition or brand identity sufficient to execute a patent estate analysis.
What is the Orange Book status of CHILDRENS COLD AND COUGH LIQ?
Featured snippet answer: Orange Book status cannot be determined without identifying the exact FDA product (brand name, active ingredients, dosage form, and manufacturer) that corresponds to “CHILDRENS COLD AND COUGH LIQ.”
OTC reality check
Many OTC cold/cough products are not listed in the Orange Book because they are not new drug applications in the same sense as prescription brand products with NDA exclusivity and generic application pathways.
What generic or private-label entry risks affect price projections?
Featured snippet answer: For OTC pediatric cold/cough liquids, the dominant “entry risk” is private label and equivalent formulations, not generic NDA entry.
Entry levers that pressure price
- availability of equivalent ingredient suppliers
- retailer switching between branded and private label
- formulation substitutions that remain compliant with pediatric labeling
What revenue exposure and price elasticity assumptions are needed for forecasting?
Featured snippet answer: Revenue exposure depends on SKU velocity and promo intensity; price elasticity depends on how close substitutes are (same ingredient classes and pediatric label strength).
Missing product identity blocks the model
To project price and revenue, the product must be mapped to:
- historical sales/units (or proxy sell-through)
- exact pack size and concentration
- channels and promo mix
- substitute set
Those cannot be established from “CHILDRENS COLD AND COUGH LIQ” alone.
Key Takeaways
- “CHILDRENS COLD AND COUGH LIQ” is not a unique drug identifier; it does not specify active ingredients, strength, manufacturer, or NDC, so the product cannot be mapped to a definable OTC SKU.
- Market sizing, competitive set construction, and defensible price projections require product-level identifiers; without them, any forecast would be non-actionable.
FAQs
-
How do I forecast OTC pediatric cold and cough liquid prices without NDC-level data?
You cannot produce a defensible SKU-level forecast; you need a unique identifier that maps to a defined product and pack size. -
Does OTC pediatric cold/cough pricing behave like prescription drug pricing?
No. OTC pricing is largely promo and retailer-driven rather than exclusivity-driven. -
What substitution patterns matter most for children’s cough and cold liquids?
Substitution is driven by overlapping symptom coverage, pediatric labeling, and pack size unit cost across brands and private label. -
How does seasonality typically impact retail price for cold/cough liquids?
Price resets and promotions often occur pre-season; realized prices then reflect demand intensity and promo depth during peak weeks. -
Are patents relevant to OTC pediatric cold/cough liquids?
Typically less so than for prescription brands; price competition is usually driven by formulation equivalence and private label dynamics rather than NDA exclusivity.
References
No sources can be cited because no product identity was provided to map “CHILDRENS COLD AND COUGH LIQ” to an FDA listing, NDC, retailer price series, or market database record.
More… ↓
